The S&P 500 Index ($SPX ) (SPY ) closed up by +0.33% on Thursday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up by +1.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.05%.  December E-mini S&P futures (ESZ26 ) rose +0.28%, and December E-mini...

Stocks Settle Mixed as Broader Market Recovers from Chip Stock Rout

The S&P 500 Index ($SPX ) (SPY ) is up by +0.13% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +1.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.57%.  December E-mini S&P futures (ESZ26 ) are up +0158%, and December E-mini...

Stock Indexes Rebound as Investors Rotate Out of Chip Stocks

The S&P 500 Index ($SPX ) (SPY ) is down by -0.57% today, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up by +0.30%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -1.71%.  December E-mini S&P futures (ESZ26 ) are down -0.58%, and December E-mini...

Stocks Pressured as Chipmaker Selloff Deepens

The S&P 500 Index ($SPX ) (SPY ) closed down by -0.02% on Tuesday, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down by -0.35%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.31%.  December E-mini S&P futures (ESZ26 ) fell -0.02%, and December E-mini...

Stocks Finish Lower Ahead of Wednesday’s CPI Report

Investors in Alnylam Pharmaceuticals Inc (Symbol: ALNY) saw new options become available today, for the September 2027 expiration.  One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 339 days until expiration the newly av

Interesting ALNY Put And Call Options For September 2027

Key PointsAlnylam cut its full-year revenue guidance due to slower-than-expected sales for Amvuttra.

Alnylam vs. Ionis: Here's the Better Bad-News Buy

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam Pharmaceuticals, Inc. News